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ABSTRACT
Background: Although FOXE1 was initially recognized for its role in thyroid 
organogenesis, more recently a strong association has been identified between 
the FOXE1 locus and thyroid cancer. The role of FOXE1 in adult thyroid, and in 
particular regarding cancer risk, has not been well established. We hypothesised 
that discovering key FOXE1 transcriptional partners would in turn identify regulatory 
pathways relevant to its role in oncogenesis. 
Results: In a transcription factor-binding array, ELK1 was identified to bind 
FOXE1. We confirmed this physical association in heterologously transfected cells 
by IP and mammalian two-hybrid assays. In thyroid tissue, endogenous FOXE1 was 
shown to bind ELK1, and using ChIP assays these factors bound thyroid-relevant 
gene promoters TPO and TERT in close proximity to each other. Using a combination 
of electromobility shift assays, TERT promoter assays and siRNA-silencing, we found 
that FOXE1 positively regulated TERT expression in a manner dependent upon its 
association with ELK1. Treating heterologously transfected thyroid cells with MEK 
inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO 
promoter activity.
Methodology: We investigated FOXE1 interactions within in vitro thyroid cell 
models and human thyroid tissue using a combination of immunoprecipitation (IP), 
chromatin IP (ChIP) and gene reporter assays. 
Conclusions: FOXE1 interacts with ELK1 on thyroid relevant gene promoters, 
establishing a new regulatory pathway for its role in adult thyroid function. Co-
regulation of TERT suggests a mechanism by which allelic variants in/near FOXE1 
are associated with thyroid cancer risk.
INTRODUCTION
Thyroid cancer is the most commonly occurring 
endocrine malignancy, accounting for 1% of all cancer 
diagnoses each year. The most common histological 
subtype is papillary thyroid cancer (PTC), a carcinoma 
of follicular cell origin, which accounts for 80% of 
thyroid malignancies. PTC demonstrates a strong genetic 
component, since it shows the highest relative risk 
(FRR = 8.60–10.30) in first degree relatives of probands 
among cancers not displaying Mendelian inheritance [1, 2]. 
FOXE1 (Forkhead Box E1), a Forkhead (FOX) 
transcription factor is essential for thyroid gland 
development [3–9], and is also required in the hormonal 
regulation of thyroglobulin (TG) and thyroid peroxidase 
(TPO) gene expression by the adult thyrocyte [10–12]. 
Recent  genetic  studies  have  identified  germline  allelic 
variation in and near FOXE1 to be strongly associated 
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with non-medullary thyroid cancer risk including single 
nucleotide variants rs965513[A] (56 kb upstream of 
FOXE1) [13–18] and rs1867277[A] (within its promoter) 
[19–21], and variation within the FOXE1 polyalanine tract 
[22–24]; resolution of causal variants responsible for the 
association with thyroid cancer has been difficult due to 
strong linkage disequilibrium between all three variants. 
Nevertheless, these allelic variants were associated with 
altered FOXE1 expression in PTC tissues [25], whereas 
complete loss of FOXE1 expression is often found in 
anaplastic thyroid cancer (ATC) [26, 27]. Conversely, 
the ‘benign’ rs965513[G] allele has been associated with 
hypothyroidism [28] and altered free T3/free T4 balance 
[13]. Together, these converging lines of evidence strongly 
suggest that FOXE1 is important for maintaining normal 
thyroid differentiation even in the adult gland. However, 
as of yet, no mechanistic data exists to explain the 
association between FOXE1 and thyroid cancer risk.
Recent studies have demonstrated that FOX proteins 
often regulate key pioneer functions via interaction with 
key transcription factors [29], dysregulation of which 
can cause cancer [30]. We reasoned that FOXE1 role 
in thyroid cancer might be explained by discovering its 
interacting partners and cognate transcriptional pathways 
(Figure 1A). We tested this hypothesis by searching for 
FOXE1 interaction partners from a panel of transcription 
factors, and found that the strongest signal was for the 
ETS  (E26  transformation-specific)  factor  ELK1.  Since 
ETS factors are already strongly implicated in thyroid 




and functional association by several experimental 
approaches. Finally, since ETS factors have been shown 
to regulate TERT (Telomerase Reverse Transcriptase) in 
cancer [32–35], we specifically examined FOXE1-ELK1 
co-regulation of this gene promoter.  
RESULTS
FOXE1 physically interacts with ETS factor 
ELK1
Firstly, we sought to identify candidate FOXE1-
interacting transcriptional cofactors using a medium 
throughput protein-DNA array technology. NThy-
ori-3.1 (NThy) thyroid cells were transiently transfected 
with either empty vector (negative control) or plasmid 
expressing Flag-tagged FOXE1 protein (FOXE1-
Flag). Forty-eight hours post-transfection the cells 
were harvested and nuclear fractions were prepared for 
subsequent analysis with Affymetrix TF-TF interaction 
arrays I and II (screening a total of 150 different 
transcription factors). Figure 1B shows the anti-Flag 
antibody versus IgG isotype negative control results for 
a  sub-region  of  array  I.  Significantly  elevated  signals, 
reflective of FOXE1-binding, were observed for several 
transcription  factors  such  as  ELK1,  c-REL,  FOXF2, 
FOXD1 and FOXI1 (the FOX proteins being likely 
false positives due to FOXE1 directly binding to their 
capture  probes). The ERK-regulated ETS  factor ELK1 
(Figure 1B) was a candidate of particular interest, given 
the importance of BRAF-ERK signalling as a driver of 
thyroid tumorigenesis. 
The  physical  association  of  FOXE1  and  ELK1 
was validated using co-immunoprecipitation (Co-IP) 
experiments, using proteins initially from transfected 
cells and then from thyroid tissue. Whole cells lysates 
were harvested from NThy cells transiently co-expressing 
FOXE1-Flag  and  HA-tagged  ELK1  (ELK1-HA), 
immunoprecipitated with an anti-Flag antibody, and then 
subjected to analysis by western blotting. Figure 1C is 
a  representative  western  blot  showing  that  ELK1-HA 
could only be precipitated with anti-Flag antibody when 
FOXE1-Flag was co-expressed. Similarly, western blots of 
reciprocal Co-IP experiments (immunoprecipitating with 
an anti-HA antibody) could only detect FOXE1-Flag when 
both proteins were co-expressed (dns). 
To  confirm  that  the  observed  ELK1/FOXE1 
interaction was not an artefact in these over-expression 
models, we next performed Co-IPs from thyroid tissue 
for endogenously expressed proteins. Figure 1D shows a 
representative western blot demonstrating that ELK1 was 
co-immunoprecipitated using an anti-FOXE1 antibody, 
but not with the corresponding IgG isotype control. The 
reciprocal experiment (immunoprecipitating with an anti-
ELK1 antibody) yielded a similar result (dns).
We  also  confirmed  physical  interaction  between 
FOXE1  and  ELK1  in  mammalian  two-hydrid  assays. 
Figure 1E shows that a construct containing the Gal4 
DNA-binding domain (DBD) joined with the C-terminus 
of FOXE1 (amino acids 164–373) weakly activated the 
Gal4-reporter gene (pGL5-luc) alone, but co-transfection 
with  a  second  construct  containing  full-length  ELK1 
tagged with the VP16 activation domain resulted in 
strongly enhanced transactivation.
Having established that the FOXE1 C-terminus is 
capable of binding ELK1, we next sought to identify the 
relevant  interaction  domain(s)  of ELK1.  Further Co-IP 
experiments were performed with a series of truncated 
ELK1-HA  proteins  in  which  previously  characterised 
ELK1 domains were deleted;  including  the ETS DBD, 
SRF (serum response factor) interacting (S), transcriptional 
repressor (R), MAPK (mitogen activated protein kinase) 
docking (M) and transcriptional activation (A) domains 
(Supplementary Figure S1) [36, 37]. Altogether, the 
following truncations were generated: (1) amino-acids 
1–309 (containing DBD, S and R domains), (2) 1–349 
(DBD, S, R and M), (3) 205–428 (S, R, M and A), (4) 
310–428 (M and A) and (5) 349–428 (A).  Unexpectedly, 
we found that all ELK1 truncations tested could be co-
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precipitated with FOXE1-Flag (Figure 1F). This would 
suggest the existence of multiple interaction motifs through 
which  FOXE1 may  bind with  ELK1. However,  ELK1 
is also known to homodimerize in solution via its own 
DBD [38]. Thus, it is also possible the DBD-containing 
truncations could be precipitated indirectly by forming 
dimers  with  endogenous  full-length  ELK1.  Of  note, 
C-terminal fragments encompassing amino acids 310–428 
consistently demonstrated a more robust interaction with 
FOXE1 as compared with regions spanning amino acids 
1–310 (Figure 1F). Interestingly, these truncations lack the 
transcriptional repressor domain (R domain), which by a 
sumoylation-dependent mechanism can disrupt ELK1’s 
interaction with cofactors [37].
ELK1 recruits FOXE1 to the TERT promoter 
A  significant  proportion  of  thyroid  cancers 
harbour oncogenic mutations with the TERT promoter. 
These mutations generate de novo ETS-factor binding 
sites that mediate TERT transactivation in response 
to  oncogenic  BRAF-ERK-signalling.  We  therefore 
considered whether FOXE1 is recruited to the TERT 
promoter via interacting with ELK1. 
In silico analysis (PROMO using version 8.3 of 
TRANSFAC [39, 40]) did not find a canonical FOX-binding 
site within the proximal TERT promoter (RYAAAYA [41]). 
Nevertheless, using formaldehyde-fixed chromatin isolated 
from thyroid tissue, chromatin immunoprecipitation (ChIP) 
revealed a 4.6-fold enrichment of FOXE1 (p < 0.01) in the 
same region of the TERT promoter (-151 to +11-bp relative 
to the TSS) that is specifically bound by ELK1 (Figure 2A).  
Supporting  the  specificity  of  this  interaction,  neither 
FOXE1 nor ELK1 DNA-binding could be detected in two 
upstream regions of the TERT promoter (located –1000 and 
–4000 bp relative to the TSS). 
To determine whether FOXE1 directly binds 
to the TERT promoter, we conducted electromobility 
Figure 1: The Forkhead factor FOXE1 physically interacts with the ETS-factor ELK1. (A) Schematic of FOXE1 binding 
to target gene and interacting with a transcriptional co-factor. FOXE1 DBD is shown as a cylinder; its C-terminal domain is shown as 
a rhomboid; and a putative interacting co-factor is shown as a hexagon. The position of the FOXE1 polyalanine tract is shown, where 
x = 11–19 alanines. (B) Potential FOXE1-interacting partners detected with the TransSignal™ (Panomics) TF-TF interaction array-I. Nuclear 
extracts from NThy cells overexpressing FOXE1-Flag protein, were mixed with the TransSignal Probe mix, and immunoprecipitated using 
either an anti-Flag antibody or IgG isotype control. Duplicate spots corresponding to the ELK1 and c-REL are boxed with a solid line and 
dotted lines respectively. The other visible spots are signals for FOXF2, FOXD1 and FOXI1 binding sites, and are likely false-positives 
produced by FOXE1 directly binding the capture probe (boxed with a dashed line). (C) Validation of the FOXE1-ELK1 interaction by 
Co-IP of exogenous epitope-tagged proteins. NThy cells were transiently transfected with varying combinations of empty, FOXE1-Flag 
and ELK1-HA expression plasmids;  immunoprecipitation was performed using an anti-Flag antibody (or IgG isotype control), and the 
western blot was probed with an anti-HA antibody. (D) Validation of the FOXE1-ELK1 interaction by Co-IP of FOXE1 and ELK1 proteins, 
endogenously  expressed  in  thyroid  tissue. Tissue  lysate was  immunoprecipitated with  an  anti-ELK1  (C-terminal  domain) monoclonal 
antibody, and the western blot probed with an anti-FOXE1 monoclonal antibody. (E) Mammalian two-hybrid assay in HEK293 cells using 
transfected Gal4-FOXE1 and ELK1-VP16 and pGL5-luc reporter. Proteins were harvested 48 hrs post-transfection and reporter assays 
performed. Values are the the mean (± SD) of three experiments, each performed in triplicate, expressed as fold increase in luciferase 
activity relative to cells transfected only with reporter. (F) Mapping the location of the FOXE1-ELK1 interaction domain, by Co-IP of 
lysates from NThy cells expressing full-length FOXE1-Flag protein with various truncated mutant forms of ELK1-HA. 
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shift assays (EMSAs) using a biotinylated-probe 
corresponding  to  the promoter  region  identified  in our 
ChIP  experiments.  We  firstly  confirmed  that  FOXE1 
protein isolated from transfected HEK293 cells was able 
to bind its previously described cognate response element 
within the TG promoter [42] (Figure 2B, at left). We then 
incubated ELK1, FOXE1 or both with the TERT probe: 
this was readily bound by ELK1, but unexpectedly was 
only  shifted  by  FOXE1 when ELK1 was  also  present 
(Figure 2B, middle). The same results were obtained 
when the TERT probe was mutated to contain the C228T 
or C250T variants that are found in thyroid cancer 
(Supplementary Figure S2). These results suggest that 
FOXE1 is only indirectly recruited to the TERT promoter 
via  its  interaction  with  ELK1,  and  that  this  indirect 
recruitment is not affected by cancer-associated mutations 
in the TERT promoter. Interestingly however, a DNA-
binding mutation (p.Ala65Val) [3] in FOXE1 abrogated 
its interaction with TERT-bound  ELK1  (Figure  2B),  
although  it  was  still  able  to  bind  ELK1  in  solution 
(Figure 2C). This suggested that FOXE1 may bind a non-
consensus site within the TERT promoter but only after 
binding with ELK1.
We then examined whether FOXE1 regulated 
TERT transcription in thyroid cells, and whether this 
effect was similar on native and mutant TERT promoters. 
Figure 2: FOXE1 and ELK1 interact with the TERT gene promoter. (A) Detection  of  FOXE1  and ELK1 binding  at  the 
TERT gene promoter by ChIP. Sheared formaldehyde-fixed chromatin was isolated from thyroid tissue and then immunoprecipitated with 
monoclonal  antibodies  raised  against  human FOXE1 and ELK1 proteins. ChIP DNA was  amplified by  real-time qPCR using primers 
specific for the proximal TERT promoter and two negative control regions located 1000- and 4000-bp upstream of the TSS. Enrichment 
of transcription factor binding was calculated as a percentage of the input DNA control.  Values are the mean average and SD of three 
independent experiments. Significant enrichments over IgG controls are highlighted (*p < 0.01, Student’s t-test). (B) Measurement of the 
DNA-binding affinity of FOXE1 and ELK1 for the TERT promoter by EMSA. Varying combinations of purified FOXE1-Flag, FOXE1A65V-
Flag and ELK-HA proteins were incubated with biotinylated TERT DNA-probe, resolved on a 6% polyacrylamide gels, and transblotted 
onto nylon membrane. (C) Determination of whether the FOXE1A65V mutant  and ELK1  can  interact  by Co-IP  of  exogenous  epitope-
tagged proteins. NThy cells were transiently transfected with varying combinations of empty, FOXE1A65V-Flag and ELK1-HA expression 




cell-line; although similar results were also found in 
SW1736 (ATC) and NThy (non-tumorigenic thyroid) 
cell-lines (Supplementary Figure S3). As shown in 
Figure 3A, overexpression of FOXE1 stimulated both 
wild-type and C228T-mutated TERT promoters by 3.8 
and 4.3-fold respectively compared with their respective 
empty vector-transfected controls. MEK inhibitor U0216 
inhibited transactivation of the TERT reporter gene to a 
similar degree in either the presence or absence of FOXE1 
(Figure  3A).  Consistent  with  our  findings  in  DNA-
binding studies noted above, mutant FOXE1A65V did not 
transactivate the TERT reporters (Figure 3A).
To confirm that TERT is regulated by endogenously 
expressed FOXE1, siRNA-mediated knockdown 
experiments were performed in SW1736 cells that 
express both FOXE1 and ELK1  (our own unpublished 
observations). FOXE1-targeting siRNA successfully 
depleted these cells of FOXE1 protein (Figure 3B, at left) 
and this was associated with a 28–40% reduction in TERT 
expression assessed by qRT-PCR (Figure 3B, at right). 
Similar repression of TERT was also detected when 
these cells were depleted of ELK1 protein (Figure 3B). 
However, simultaneous depletion of both factors caused 
significant cell death, to such an extent that the effect upon 
TERT expression could not be measured.
Figure 3: FOXE1 regulates TERT transcription in thyroid cancer cells. (A) Determination of the transcriptional activity of 
FOXE1 upon the TERT gene promoter. KTC1 cells were transiently transfected with either wild-type or C228T TERT-luc, and different 
combinations of FOXE1-Flag, FOXE1A65V-Flag or empty Flag expression plasmids. Twenty-four hours post-transfection the cells were 
treated for a further 24 hours with 10 µM U0126 or vehicle, prior to whole cells lysates being harvested for luciferase reporter assays. 
Luciferase results are the mean (± SD) of three experiments, each performed in triplicate, expressed as fold change in luciferase activity 
relative to empty vector transfected cells. (B) Measurement of the changes in TERT mRNA transcription in response to depleting FOXE1 
and ELK1 proteins. SW1736 cells were transiently transfected with FOXE1/ELK1 specific-siRNA (or scrambled siRNA control),  then 
RNA and protein harvested from the cells 48 hrs later. FOXE1 and ELK1 levels were ascertained by western blotting, whilst TERT mRNA 
expression were quantified by real-time qRT-PCR. Significant changes are highlighted (*p < 0.05, Student’s t-test).
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MEK inhibition in thyroid cancer cells disrupts 
the FOXE1-ELK1 interaction
As  noted  above,  treatment  with  a MEK  inhibitor 
reduced FOXE1-mediated transactivation of the TERT 
reporter gene. To determine whether this was due to loss 
of  physical  interaction  between  FOXE1  and ELK1, we 
performed Co-IP assays using lysates from transfected 
SW1736 ATC cells containing the BRAFV600E oncogene. 
As  shown  in  Figure  4A,  inhibition  of  the  MEK/ERK 
activity partially inhibited (by approximately 20%) the 
interaction between FOXE1 and ELK1 in solution. This 
effect was seen following treatment with two different 
MEK inhibitors, and so was likely to be a specific effect 
of MEK inhibition. Conversely, when all known phospho-
accepting Ser/Thr [49] (shown in Supplementary Figure S1) 
were  mutated  in  ELK,  this  ERK-unresponsive  mutant 
ELK1-HA also showed a significant reduction in its ability 
co-immunoprecipitate FOXE1-Flag (Figure 4A). Similar 
results were also obtained in KTC1 and NThy cells (dns). 
These data suggest that phosphorylation of ELK1 positively 
regulates its interaction with FOXE1. We explored this 
further in mammalian two-hybrid assays. As shown in 
Figure 4B, the interaction between Gal4-FOXE1 and VP16-
ELK1 in regulating pGL5-Luc within SW1736 cells was 
diminished by 31% after treatment with U0126, consistent 
with the result from solution binding assays. Again, similar 
results were also obtained in KTC1 and NThy cells (dns). 
FOXE1-ELK1 interaction is also functionally 
relevant for TPO promoter activity
Next we examined by ChIP whether FOXE1 and 
ELK1 were co-bound to the human TPO promoter, in a 
region orthologous to the well-characterized FOXE1-
responsive element in the rat TPO promoter (–177 to 
–23 bp relative to the transcriptional start site) [10–12]. 
Our in silico analysis (PROMO using version 8.3 of 
TRANSFAC) also revealed this region to harbour predicted 
ETS factor binding sites. ChIP assays were performed using 
formaldehyde fixed chromatin isolated from thyroid tissue 
[26]. As expected we detected FOXE1 binding within close 
proximity to the TPO TSS (2.1-fold enrichment over the 
IgG negative control, p < 0.01) (Figure 5A). In contrast, 
two upstream promoter regions without predicted FOX-
binding  sites  (˗1000  and  ˗4000  bp  relative  to  the TSS) 
showed no enrichment for FOXE1-binding (Figure 5A). 
In agreement with our hypothesis that FOXE1 and ELK1 
functionally interact on the TPO promoter, we also 
detected enrichment for DNA-binding of ELK1 (5.1-fold 
enrichment over IgG negative control, p < 0.01) close to 
the TPO TSS. Again, no significant enrichment of ELK1 
binding was observed in the upstream promoter regions 
(Figure 5A). 
We  then  investigated  whether  ELK1  affected 
FOXE1-stimulated transcription from the human TPO 
promoter. Overexpression of either FOXE1 or ELK1 in 
Figure 4: MAPK inhibition in thyroid cancer cells disrupts the binding of FOXE1 to ELK1. (A) Determination of the effect 
of MEK inhibition upon the FOXE1-ELK1 interaction. SW1736 cells were transiently transfected with various combinations of FOXE1-
Flag and WT/mutant ELK-HA, treated with 10 µM MEK inhibitor or vehicle control, and then immunoprecipitation was performed using 
an anti-Flag antibody, and the western blot probed with an anti-HA antibody. (B) Mammalian two-hybrid assay in SW1736 cells using 
transfected Gal4-FOXE1 and ELK1-VP16 and pGL5-luc reporter. Twenty-four hours post-transfection, the cells were treated with 10 µM 
U0126 or vehicle control for a further 24 hrs, prior to the harvest of protein lysates and subsequent reporter assay. Values are the the mean 
(± SD) of three experiments, each performed in triplicate, expressed as fold increase in luciferase activity relative to cells transfected only 
with reporter.  Significant changes are highlighted (*p < 0.05, Student’s t-test).
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NThy cells stimulated TPO reporter activity by 12 and 
2.5-fold respectively, relative to empty vector control 
(Figure 5B). In support of our hypothesis that these factors 
co-operate to enhance gene transcription, simultaneous 
co-expression of ELK1 and ELK1 enhanced TPO reporter 
activity by 2.3-fold, relative to FOXE1 alone. Consistent 
with our hypothesis  that MEK-ERK inhibition disrupts 
FOXE1-ELK1 interaction, this enhancement of promoter 
activity  was  lost  following  treatment  with  a  MEK 
inhibitor. Similarly, an ERK-unresponsive ELK1 mutant 
was also found not to be capable of enhancing FOXE1-
stimulated reporter activity. 
Expansion of the FOXE1 Polyalanine Tract
In our previous study we demonstrated using gene 
reporter assays that the FOXE116Ala –thyroid encoded by 
the cancer risk allele was less transcriptionally active 
Figure 5: FOXE1 and ELK1 interact with the TPO gene promoter. (A) Detection of FOXE1 and ELK1 binding at the TPO gene 
promoter by ChIP. Sheared formaldehyde-fixed chromatin was isolated from thyroid tissue and then immunoprecipitated with monoclonal 
antibodies raised against human FOXE1 and ELK1 proteins. ChIP DNA was amplified by real-time qPCR using primers specific for the 
proximal TPO promoter and two negative control regions located 1000- and 4000-bp upstream of the TSS. Enrichment of transcription 
factor binding was calculated as a percentage of the input DNA control.  Values are the mean average and SD of three independent 
experiments. Significant enrichments over IgG controls are highlighted (*p < 0.01, Student’s t-test). (B) Characterizing FOXE1-ELK1 
mediated regulation of the TPO gene promoter. NThy cells were transiently transfected with TPO-luc and different combinations of 
FOXE1, ELK1, mutant ELK1 or empty expression plasmids. Twenty-four hours post-transfection the cells were treated for a further 24 hrs 
with 10 µM U0126 or vehicle, prior to whole cells lysates being harvested for luciferase reporter assays. Luciferase results are the the 
mean (± SD) of three experiments, both performed in triplicate, expressed as fold increase in luciferase activity relative to empty vector 
transfected cells. Significant changes are highlighted (*p < 0.05, Student’s t-test).
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than the FOXE114Ala (encoded by the major allele in all 
populations)  on  thyroid-gene  specific  promoters  [23]. 
Here, we extended these experiments to encompass the 
majority of polyalanine tract alleles observed in normal 
populations (11–17 alanine residues). Figure 6A shows 
the results of gene reporter assays which demonstrate 
an inverse correlation between polyalanine tract length 
and the ability of FOXE1 to transactivate three different 
FOXE1-responsive promoters (the native human TPO and 
TG promoters, and a synthetic construct Z16TKLUC [3]). 
In mammalian two hybrid experiments, we observed that 
increasing polyalanine tract length also had an inhibitory 
effect  upon  Gal4-FOXE1  and  VP16-ELK1  stimulated 
promoter activity (Supplementary Figure S4). In contrast, 
the length of the polyalanine tract did not moderate 
FOXE1 transactivation of either wild-type or mutant 
(C228T or C250T) TERT gene promoters (Figure 6B). 
DISCUSSION
Little is known about the role of FOXE1 in the adult 
thyroid gland, or about those mechanism(s) by which 
variants in or near FOXE1 (all of which are in tight linkage 
disequilibrium) are associated with thyroid cancer risk. 
We hypothesized that identifying FOXE1 transcriptional 
partners would shed light on the mechanism of its 
association with thyroid cancer. In this paper we have 
identified that FOXE1 binds with ELK1 and functionally 
co-regulates TERT in thyroid cells. Our data highlights 
a new biological pathway by which FOXE1 binds with 
ELK1 to alter transcriptional function of thyroid genes.
Other FOX family members have previously been 
noted to regulate gene transcription via binding with 
ETS factors, including FoxC2/Etv2 [43] and FoxO1/
Ets1 [43, 44]. In the case of FoxC2/Etv2 co-regulation 
Figure 6: The impact of polyalanine tract length upon FOXE1 mediated transcriptional regulation. NThy cells were co-
transfected with FOXE1-Flag expressing plasmids of varying polyalanine tract size (0-17Ala) and (A) reporter plasmids containing known 
FOXE1-responsive elements – the native TPO and TG promoters and a synthetic Z16TKluc; or (B) reporter plasmids containing the wild-
type and mutant (C228T or C250T) TERT gene promoters. Twenty-four hours post-transfection, cell lysates were harvested and luciferase 
assays performed (*p < 0.01 between polyalanine variants on each reporter gene, One-Way ANOVA).
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of vascular endothelial promoters, composite cis-acting 
motifs containing a consensus FOX DNA binding element 
upstream of a consensus ETS element have been identified 
in a large number of endothelial gene promoters [43]. In 
our study, the well-studied ETS response element in TERT 
was not obviously nearby a consensus FOX response 
element; nevertheless, we were able to show that FOXE1 
bound this TERT enhancer when ELK1 was also present 
and that this binding was abolished by a DNA-binding 
mutation in FOXE1. Our data are most consistent with a 
mechanism by which ELK1 changes the TERT promoter 
structure in some manner that enables recognition of a 
non-consensus element by FOXE1; such a mechanism has 
also been reported for FOXM1 for which non-consensus 
binding  sites  were  identified  throughout  the  genome 
that nevertheless required an intact Forkhead DBD [45]. 
Diversity of Fox domain DNA binding has also been 
identified  using  evolutionary  approaches,  suggesting  a 
model whereby conformational rearrangement of the 
DBD through specific co-partner interaction changes its 
sequence recognition motifs [46]. 
The particular role of ETS factors in malignancy has 
been known for some time: activation/overexpression of 
ELK1 has been implicated in the pathogenesis of several 
malignancies including breast and bladder [47, 48] and 
the TCF (ternary complex factor) subfamily, consisting 
of ELK1, ELK3 and ELK4, are particularly sensitive to 
ERK-mediated  phosphorylation  [49].  Our  study  is  the 
first to identify a possible role for FOX:ETS interaction 
in malignancy.  
The  importance  of  finding  a  new  mechanism 
of TERT regulation is underscored by the plethora of 
emerging data regarding this oncogene in malignancy. 
Somatic mutations in the TERT  promoter  were  first 
identified in melanoma [50, 51] and have been observed 
at high frequency in multiple cancer types, including 
those of the thyroid, central nervous system, and bladder 
[52–54]. The two hot-spot mutations (chr5:1,295,228C > T, 
“C228T”, and chr5:1,295,250C > T, “C250T”) both 
create a putative consensus binding site (GGAA) for ETS 
transcription factors that in turn drive increased TERT 
expression [50]. We and others have previously shown 
that MEK inhibition successfully blocked transactivation 
of TERT promoter constructs containing these oncogenic 
mutations [55, 56]. In the present study we have now 
identified that FOXE1 co-regulates TERT via interaction 
with ELK1, and that MEK inhibition partially abrogates 
this interaction. Our data raise the opportunity for 
discovering new therapies directed at TERT inhibition via 
targeting this interaction.
Finally, with respect to the association between 
variants in/near FOXE1 and mechanisms of thyroid cancer 
risk, our data provides a new mechanism by which FOXE1 
can affect cancer development via TERT upregulation. 
It remains unclear how these FOXE1 variants affect 
function: one study proposed that rs1867277 functionally 
alters binding of USF1/USF2 transcription factors within 
the FOXE1 proximal promoter [19]; other work has 
proposed that rs965513 identifies a group of long-range 
enhancer elements that regulates FOXE1 expression 
[57]. Our own previous work suggested that a longer 
FOXE1 polyalanine tract (FOXE116Ala) is transcriptionally 
impaired upon the TPO and TG gene promoters [23], and 
here we demonstrate that this negative relationship holds 
true for a wide-range of naturally occurring polyalanine 
tract variants. We also demonstrate that increasing 
length of the polyalanine tract length negatively impacts 
upon the ability of FOXE1 to interact with ELK1. This 
concept that impaired FOXE1 function drives thyroid 
oncogenesis is also supported by recent description of a 
germline missense FOXE1 mutation in one family with 
non-medullary  thyroid cancer [58], and also by finding 
somatic FOXE1 missense mutations in sporadic thyroid 
cancer [59]. However, in this study we were unable to 
show an effect of the polyalanine tract expansion per se 
on FOXE1-mediated transcriptional regulation of TERT. 
Thus, the functional effects of the polyalanine tract appears 
to be promoter-context dependent, and it may influence 
oncogenic pathways via, as of yet, unidentified FOXE1 
regulated genes. Further studies using manipulation of 
endogenous FOXE1 polyalanine tracts, and global gene 
expression analysis, will be required to explore this 
hypothesis in more detail.
Overall, our work sheds new light on the role 
of FOXE1 in thyroid cancer susceptibility, and the 
transcriptional  partnership  between  FOXE1  and  ELK1 
opens new therapeutic possibilities, either via targeting 
of  FOXE1-ELK1  binding  (in  a  similar  manner  to  the 






Plasmids were generated using PCR-cloning and 
site-directed mutagenic techniques (PCR primer sequences 
are provided in Supplementary Table S1). For Co-IP 
experiments, both full-length and truncated ELK1 coding 
sequences were cloned into the NotI-XhoI site of pCMV-
HA-N vector (Takara Bio Inc, Japan). The full-length 
FOXE1 coding sequence was cloned into EcoRI-BamHI 
site  of  p3XFlag-CMV-7.1  (Sigma-Aldrich,  St  Louis, 
MO, USA). For mammalian two-hybrid experiments, 
the pACT-ELK1 construct was generated by cloning the 
ELK1 coding sequence into the BamHI-KpnI site of the 
pACT vector (Promega, Madison, WI, USA). The pBIND-
FOXE1 construct was created by cloning the coding 
sequence of the FOXE1 C-terminus into the BamHI-KpnI 
site of the pBIND vector (Promega). For gene reporter 
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experiments, a 474 bp region of the human TERT promoter 





plasmid maxi kit, according to the manufacturer’s 
instructions (Qiagen, Hilden, Germany).
Cell culture
HEK293 cells were grown in DMEM, and NThy-
ori-3.1 (non-tumorigenic thyroid), SW1736 (BRAFV600E, 
TERTC228T,  p53-null  ATC)  and  KTC1  (BRAFV600E, 
TERTC250T, p53 positive PTC) cells were grown in RPMI. 
All growth media was supplemented with 10% fetal calf 
serum, 50 U/ml penicillin, 50 μg/ml  streptomycin,  and 
cells were maintained in 5% CO2 concentration at 37°C. 
The growth media of the KTC1 cell-line was additionally 
supplemented with 1% non-essential amino acids (all 
reagents from Thermo Fisher Scientific, Waltham, MA, 
USA). The  identity of each cell-line was confirmed by 




Cells were serum-starved for 24 hrs prior to be 
treated with either 10 µM U0126 or 50 µM PD98059 
(Merk KGaA, Darmstadst, Germany), or DMSO (Sigma-
Aldrich) vehicle control. For Co-IP and luciferase reporter 
experiments, cells were treated for 1 hr and 24 hrs, 
respectively, prior to cell-lysis.
siRNA knockdown
 The day before transfection, SW1736 cells were 
plated in a 6-well culture plate at density of 2 × 105 cells 
per well. Cells were transiently transfecting with Roche’s 
XtremeGene siRNA transfection reagent (Roche, Basel, 
Switzerland); with 160 pmoles of FOXE1/ELK1 specific 
siRNA or AllStars negative siRNA control (Qiagen). 
Forty-eight hours after transfection, total RNA was 
extracted using an RNeasy Plus mini kit (Qiagen). 
Western blot
Firstly, the protein concentration of each whole 
cell/nuclear lysates was determined using the RC DC 
Protein Assay kit (Bio-Rad, Hercules, CA, USA), 
and then 10 mg of each protein sample was resolved 
by  SDS-PAGE  and  electroblotted  onto  Hybond  ECL 
membrane  (GE Healthcare Life Sciences, Chicago,  IL, 
USA).  The membrane was incubated overnight at 4°C 
with  either  anti-FLAG  (M2)  (Sigma-Aldrich,  #F1804); 




using dilutions recommended by the manufacturer. The 
blot was then probed for 1 hr at room temperature with 
a 1:10,000 dilution of goat anti-rabbit/mouse, IgG HRP-
linked  antibody  and  developed  using  the  ECL-Prime 
Western Blotting Detection Reagent (GE Healthcare Life 
Sciences).  Densitometric analysis of western blots was 
performed using a multi-gauge imaging system (FujiFilm, 
Tokyo, Japan).
RT-PCR
Contaminating genomic DNA was removed using 
DNAse I and RNeasy Plus mini kit (Qiagen), and then 
cDNA was generated using Superscript III reverse 
transcriptase (Thermo Fisher Scientific). Gene expression 
was determined using Taqman probes (Thermo Fisher 
Scientific)  and  run  on  an ABI7900HT. Ribosomal  18S 
expression was used as a normaliser in all experiments. 
Mammalian two-hybrid and luciferase reporter 
assays
The day before transfection, HEK293 and SW1736 
cells were plated in a 24-well culture plate at density 
of 1 × 105 and 5 × 104 cells per well respectively. 
For luciferase reporter assays, cells were transiently 
transfected with Roche’s XtremeGene HP liposomal-based 
transfection reagent; with 500 ng firefly luciferase reporter 
plasmid, 50 ng renilla luciferase reporter plasmid and 
100 ng of cDNA expression plasmid (or empty expression 
vector control). For mammalian two-hybrid assays, cells 
were transfected with 1 µg pGL5-luc reporter and 100 ng 
each  of  the  Gal4-FOXE1  and VP16-ELK1  expression 
plasmids. Transfected cell were incubated for 24 hr, before 
they were lysed in 100 µl of 1X Promega passive lysis 
buffer (Promega). 
Transcription factor interaction array
The TranSignal™ TF-TF Interaction Arrays I 
and II (Affymetrix, Santa Clara, CA, USA) was used 
to screen for interactions between FOXE1 and 150 
different  transcription  factors.  Briefly,  nuclear  protein 
was extracted from NThy-ori-3.1 cells transiently 
transfected with a 3XFlag-FOXE1 expression plasmid. 
Nuclear lysate was incubated with the biotin-labeled, 
double-stranded oligonucleotide probes provided, 
allowing the transcription factor cis-elements to bind the 
Flag-tagged FOXE1 protein in the sample extract. An 
immunoprecipitation was then performed using a mouse 
monoclonal anti-Flag (M2) antibody (Sigma-Aldrich, 
F1804), to pull out the transcription factor cis-elements 
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interacting  with  FOXE1.  To  control  for  non-specific 
binding an immunoprecipitation with IgG (Thermo Fisher 
Scientific,  #31903)  was  performed  in  parallel.  Non-
specific binding was then washed away. The cis-elements 
were bound to FOXE1, and the anti-Flag (M2) antibody 
were then eluted and hybridized to the TranSignal Array 
membrane (one membrane per sample and a IgG negative 
control), and interactions detected using a horse-radish 
peroxidase (HRP)-based chemiluminescent detection 
system.
Co-immunoprecipitation
Whole cell lysates were prepared with chilled 
protein lysis buffer (0.1% Triton-X100, 150 mM NaCl, 
1 mM EGTA, 1 mM EDTA and 20 mM Tris-HCl, pH 7.5), 
containing 1X Halt protease and phosphatase inhibitor 
cocktail  (Thermo  Fisher  Scientific).  For  overexpressed 
exogenous protein, 300 µl of lysate was prepared from 
approximately 1 × 106 transfected NThy-ori-3.1 cells. 
Endogenous proteins were harvested in 1 ml of lysis 
buffer isolated from approximately 2 × 107 cells. For 
each immunoprecipitation, the lysates were combined 
with 50 µl Dynabeads® Sheep anti-Mouse or anti-Rabbit 
IgG (Thermo Fisher Scientific) combined with 1 µg of 
precipitating primary antibody (or IgG negative control), 
and incubated overnight at 4°C. Flag-tagged FOXE1 and 
HA-tagged ELK1 were precipitated with anti-Flag (M2) 
(Sigma-Aldrich, F1804) and anti-HA (Cell Signalling 
Technology, #3724) antibodies respectively. Endogenous 
FOXE1 and ELK1 were precipitated with  anti-FOXE1 
[EPR6843]  (Abcam, Cambridge, UK;  #ab134129)  and 
anti-ELK1 [E277] (Abcam, #ab32106) respectively. The 
following day, the beads were subjected to six 1 ml washes 
with  ice-cold  lysis buffer. Finally,  the purified proteins 
were eluted in 20 µl laemmeli buffer incubated at 95°C 
for 10 mins. 
Chromatin immunoprecipitation
Samples of frozen Graves’ thyroid tissue were 
obtained from the Neuroendocrine Tumor Bank located 
at  the  Kolling  Institute,  Royal  North  Shore  Hospital. 
Approval for use of these samples was obtained from the 
local institutional human research ethics committee.
Formaldehyde cross-linked chromatin was 
prepared from Graves’ thyroid tissue using a protocol 
adapted from the methodology developed by the Myers 
laboratory [62]. Briefly, 50–100 mg ground frozen tissue 
was fixed in phosphate buffered saline (PBS) containing 
1% formaldehyde, incubated at room-temperature for 
10 mins; and then inactivated by the addition of Glycine 
to a final concentration of 125 mM. Fixed cells were then 
lysed in 1 ml ice-cold Farnham lysis buffer (0.5% NP-40, 
85 mM KCl and 5 mM PIPES, pH 8.0), and this was then 
centrifuged at 16,000 g for 5 mins at 4°C. The supernatant 
was discarded and the nuclear pellet was resuspended in 
1 ml ice-cold RIPA (Radioimmunoprecipitation Assay) 
buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS 
and PBS, pH 7.5). The nuclear lysates were sonicated on 
ice for 10 mins (20 × 30 sec bursts), and the shearing of 
the chromatin into 100–600 bp fragments was confirmed 
by agarose gel analysis. The preparation was then cleared 
of debris by centrifugation at 16,000 g for 5 mins at 4°C; 
and the supernatant transferred to a new tube. For each 
ChIP purification, the nuclear lysates were combined with 
200 µl Dynabeads® Sheep anti-Mouse (or Rabbit) IgG 
combined with 10 µg of either anti-FOXE1 [EPR6843] 
(Abcam,  #ab134129)  or  anti-ELK1  [E277]  (Abcam, 
#ab32106) precipitating primary antibody (or IgG negative 
control), and incubated overnight at 4°C. The following 
day, the beads were subjected to six 1 ml washes with ice-
cold LiCl wash buffer (500 mM LiCl,   1% NP-40, 1% 
sodium deoxycholate, 100 mM Tris pH 7.5); and then a 
single wash with 1 ml ice-cold Tris-EDTA buffer (0.1 mM 
EDTA, 10 mM Tris-HCl, pH 7.5). The purified ChIP DNA 
was then eluted from the beads in 200 µl elution buffer 
(1% SDS,  0.1 M  NaHCO
3
), incubated at 65°C for 1 hr. 
Finally, the DNA was reverse cross-linked by a further 
overnight incubation at 65 oC and then purified using a 
PCR clean-up kit (Promega).
ChIP DNA was amplified using Qiagen’s HotStart 
Taq DNA polymerase, according to the manufacturer’s 
instructions. The primers sequences used to amplify 
regions of the TERT and TPO promoters can be made 
available upon request. 
Electro-mobility shift experiments
Expression and purification of recombinant proteins
 Sub-confluent HEK293 cells grown in 6 cm petri 
dishes were transfected with a total of 10 µg of FOXE1 
or ELK1 cDNA expression plasmid per plate. Forty-eight 
hrs later nuclear extracts were prepared using an NE-
PER Extraction Kit (Thermo Scientific), according to the 
manufacturer’s instructions. The lysate was then combined 
with 50 µl Dynabeads® Sheep anti-Mouse (or Rabbit) IgG 
combined with 1 mg of precipitating primary antibody; 
and the beads were washed as described previously 
(see co-immunoprecipitation method). The proteins of 
interest were eluted from the beads by the addition of 
250 µl elution buffer (100 mM Glycine-HCl, pH 3.0) to 
the pelleted beads, which were then incubated at RT for 
5 mins. Then, the sample was centrifuged at 16,000 g at 
4°C for 5 mins, and the resulting supernatant transferred 




transferred to a pre-chilled 1.5 ml tube.
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DNA binding reaction and electrophoresis
 For  each binding  reaction, 1 µg of purified protein 
was incubated at room temperature with biotin-labelled 
oligonucleotide probe comprising an 83 bp region of the 





To provide a positive control for FOXE1 DNA-binding 
a  probe  comprising  the K  region  of  the  rat  thyroglobulin 
promoter [42] was used; which contains a verified FOXE1 
binding  site  (5ʹ-[Btn]GAGGGAGTTCCTGTGACTA 
GCAGAGAAAACAAAGTGAGCCAC-3ʹ).  The  protein 
and DNA were combined in binding buffer consisting of 150 
mM KCl, 50 ng/μL Poly (dI-dC), 10% glycerol and 10 mM 
Tris (pH 7.5), and this was incubated at RT for 30 mins. The 
protein-DNA complexes were resolved by electrophoresis on a 





Differences in transcriptional activity/gene 
expression were analysed using Student’s t-test or one-
way ANOVA.
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